Form 4: Agios Pharmaceuticals Director Executes Stock Option and Sells Shares

Director David Scadden of Agios Pharmaceuticals exercised stock options and sold a portion of the acquired shares on December 11, 2024.

Summary

• David Scadden, a director at Agios Pharmaceuticals, executed a transaction involving the company's stock on December 11, 2024.
• He exercised stock options to acquire 200 shares of common stock at a price of $18.09 per share.
• Following the exercise, he sold 200 shares of common stock at a price of $46.28 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
• After these transactions, Mr. Scadden beneficially owns 15,483 shares of common stock directly and 29,107 stock options.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a director's stock transactions. It doesn't indicate any positive or negative sentiment, it is a neutral event.

Positives

• The director's stock option exercise and sale were conducted under a pre-arranged trading plan, suggesting a planned and orderly transaction.

Risks

• The sale of shares by a director could be perceived negatively by the market, although it was part of a pre-planned trading strategy.

Industry Context

This is a routine filing related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of insider trading.
• The reported transactions are typical for directors who receive stock options as part of their compensation.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it is a routine insider transaction.

Key Dates

Keywords

Agios Pharmaceuticals, stock options, insider trading, Rule 10b5-1, David Scadden, share sale, director transaction